3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Lung Neoplasms
7
Non Small Cell Lung Cancer Metastatic
3
Neoplasm Metastasis
3
Recurrence
2
Advanced Non-Small Cell Lung Cancer
2
ALK Positive Non-small Cell Lung Cancer
2
Sexual Dysfunction, Physiological
1
Non-Small Cell Lung Cancer ALK-positive
1
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
1
Neurofibromatosis 1
1
Neoplasms
1
Neoadjuvant Non-Small Cell Lung Cancer
1
NSCLC
1
Meningeal Carcinomatosis
1
Lung Diseases
1
Hyperlipidemias
1
Hereditary Sensory and Autonomic Neuropathies
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
1
Adenocarcinoma of Lung
1
ALK-positive Non-small Cell Lung Cancer
1
ALK-positive NSCLC
1
Interventions
Carboplatin
18
Pemetrexed
10
Paclitaxel
6
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Drug Delivery Systems
2
Docetaxel
2
Bronchoscopy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zipalertinib
1
zimberelimab
1
toripalimab
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
lorlatinib
×
Thoracic
×
Clear all
NCT05167500
2023-03-30
LORLAPULM
Fundación GECP
Completed
118 enrolled